A two-dose hepatitis B vaccine regimen: Proof of priming and memory responses in young adults

Vaccine

Volumn 16, Issue 6, 1998, Pages 624-629

  Marsano, Luis S ^a   West, David J ^b   Chan, Ivan ^b   Hesley, Teresa M ^b   Cox, Jenny ^a   Hackworth, Vernon ^a   Greenberg, Richard N ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hepatitis B; Hepatitits B vaccine; Immunologic memory

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; IMMUNOLOGICAL MEMORY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOLOGIC MEMORY; MALE;

EID: 0032053422     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00233-8     Document Type: Article

References (13)

1. 1 West, D.J. Scope and design of hepatitis B vaccine clinical trials. In: Hepatitis B Vaccines in Clinical Practice (Ed. Ellis, R. W.). Marcel Dekker, New York, 1993, pp. 159-177.
2. 2 Sitrin, R.D., Wampler, D.E. and Ellis, R.W. Survey of licensed hepatitis B vaccines and their production processes. In: Hepatitis B Vaccines in Clinical Practice (Ed. Ellis, R.W.). Marcel Dekker, New York, 1993, pp. 83-101.
3. 3 Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendation of the Immunization Practices Advisory Committee ACIP). Morbid. Mortal. Wkly Rep. 1991, 40 (RR-13), 1-25.
4. 4 National Center for Health Statistics (S. Abraham). Obese and overweight adults in the United States. Vital and Health Statistics, Series 11, No. 230, DHHS Pub. No. 83-1680. Public Health Service, Washington, US Government Printing Office, January 1983.
5. 5 SAS Institute, Inc. SAS/STAT User's Guide, 1994.
6. 6 Wood, R.C., MacDonald, K.L., White, K.E., Hedberg, C.W., Hanson, M. and Osterholm, M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993, 270, 2935-2939.
7. 2 tests. Biometrics 1954, 10, 417-451.
8. 8 Mantel, N. and Haensel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst. 1959, 22, 719-748.
9. 9 West, D.J. Clinical experience with hepatitis B vaccine. Am. J. Infect. Control 1989, 17, 172-180.
10. 10 West, D.J., Brown, K.R., Miller, W.J., Matthews, H., Zajac, B.A. Persistence of anti-HBs in recipients of a yeast recombinant hepatitis B vaccine. In: Viral Hepatitis and Liver Disease (Ed. Zuckerman, A.J.). Alan R. Liss, Inc., New York, 1988, pp. 1043-1046.
11. 11 West, D.J. and Calandra, G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996, 14, 1019-1027.
12. 12 Jilg, W., Schmidt, M. and Deinhardt, F. Four-year experience with a recombinant hepatitis B vaccine. Infection 1988, 17, 70-76.
13. 13 Milne, A. and Waldon, J. Recombinant DNA hepatitis B vaccination in teenagers: effect of a booster at 5 1/2 years. J. Infect. Dis. 1992, 166, 942.